drugset / Trial / NCT03964688

Effect of Vitamin C in Autologous Stem Cell Transplantations

NCT03964688

Phase 2 Completed 47 enrolled Maastricht University Medical Center
RandomizedParallel-groupQuadruple-blindTreatment

Summary

In the study the investigators will randomize patients that receive an autologous stem cell transplantation for myeloma or lymphoma for treatment with vitamin C or placebo during 6 weeks. Primary endpoint will be immune recovery.

Timeline

Start
2019-12-10
Primary completion
2022-03-01
Completion
2022-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Vitamin C Other / unclassified Intravenous

Indications